- B-cell lymphoma.
Epcoritamab is a
bispecific CD20-directed CD3 T-cell engager.
Epcoritamab was co-developed by
AbbVie and Genmab.
Epcoritamab was approved...
-
autoimmune diseases. Proprietary,
marketed with partners: Epkinly/Tepkinly (
epcoritamab) for the
treatment of Relapsed/refractory
diffuse large B-cell lymphoma...
- 2027 and is
awaiting approval from the Food and Drug
Administration for
epcoritamab, a blood-cancer
therapy under development in
partnership with Genmab...
-
Denintuzumab mafodotin§
Elotuzumab Emactuzumab Emibetuzumab§ Enoblituzumab§
Epcoritamab Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§
Gemtuzumab ozogamicin...
-
enzastaurin (USAN)
Eohilia epafipase (INN)
epalrestat (INN)
epanolol (INN)
epcoritamab (INN)
epelestat (INN)
eperezolid (INN)
eperisone (INN)
epervudine (INN)...
-
asthma Enoti****ab mab
human DLL4
Ensituximab mab
chimeric MUC5AC
cancer Epcoritamab Epkinly BiTE
humanized CD3, CD20 Y
diffuse large B-cell
lymphoma Epitumomab...
-
tisagenlecleucel (Kymriah) treatment. Cell
therapy Checkpoint inhibitor Epcoritamab Gene
therapy Immune checkpoint Fox M (July 12, 2017). "New Gene Therapy...
- emacizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab,
epcoritamab, glofitamab.
Among the bsAb
programs currently under development, the...
-
Teclistamab L01FX25
Mosunetuzumab L01FX26
Mirvetuximab soravtansine L01FX27
Epcoritamab L01FX28
Glofitamab L01FX29
Talquetamab L01FY01
Pertuzumab and trastuzumab...
-
Denintuzumab mafodotin§
Elotuzumab Emactuzumab Emibetuzumab§ Enoblituzumab§
Epcoritamab Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§
Gemtuzumab ozogamicin...
